Tempest Therapeutics (TPST) Non-Current Assets (2012 - 2026)
Tempest Therapeutics (TPST) posted Non-Current Assets of $8.7 million for Q4 2025, down 4.02% sequentially from $9.0 million in Q3 2025, and down 13.5% YoY from $10.0 million in Q4 2024.
Tempest Therapeutics (TPST) Non-Current Assets (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $8.7 million in Q4 2025.
- Quarterly Non-Current Assets fell 13.5% year-over-year to $8.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.8 million (down 11.96% YoY) and the FY2025 annual result came in at $8.7 million, down 13.5% from the prior year.
- Non-Current Assets fell to $8.7 million in Q4 2025 per TPST's latest filing, from $9.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $13.1 million in Q4 2022 and troughed at $2.9 million in Q3 2022.
- A 5-year average of $8.4 million and a median of $9.6 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets plunged 39.16% in 2022, then surged 301.37% in 2023.
- Over 5 years, Non-Current Assets stood at $4.3 million in 2021, then soared by 207.35% to $13.1 million in 2022, then dropped by 14.45% to $11.2 million in 2023, then fell by 10.91% to $10.0 million in 2024, then dropped by 13.5% to $8.7 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $8.7 million, $9.0 million, and $9.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.94 Mn |
| Dec 31, 2025 | 8.66 Mn |
| Sep 30, 2025 | 9.03 Mn |
| Jun 30, 2025 | 9.38 Mn |
| Mar 31, 2025 | 9.73 Mn |
| Dec 31, 2024 | 10.01 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | 10.62 Mn |
| Mar 31, 2024 | 10.88 Mn |
| Dec 31, 2023 | 11.24 Mn |
| Sep 30, 2023 | 11.70 Mn |
| Jun 30, 2023 | 12.21 Mn |
| Mar 31, 2023 | 12.66 Mn |
| Dec 31, 2022 | 13.14 Mn |
| Sep 30, 2022 | 2.91 Mn |
| Jun 30, 2022 | 3.04 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 4.59 Mn |
| Jun 30, 2021 | 5.00 Mn |